128 related articles for article (PubMed ID: 38496663)
1. Lineage commitment pathways epigenetically oppose oncogenic Gαq/11-YAP signaling in dormant disseminated uveal melanoma.
Kadamb R; Anton ML; Purwin TJ; Chua V; Seeneevassen L; Teh J; Angela Nieto M; Sato T; Terai M; Roman SR; De Koning L; Zheng D; Aplin AE; Aguirre-Ghiso J
bioRxiv; 2024 Mar; ():. PubMed ID: 38496663
[TBL] [Abstract][Full Text] [Related]
2. MacroH2A impedes metastatic growth by enforcing a discrete dormancy program in disseminated cancer cells.
Sun D; Singh DK; Carcamo S; Filipescu D; Khalil B; Huang X; Miles BA; Westra W; Sproll KC; Hasson D; Bernstein E; Aguirre-Ghiso JA
Sci Adv; 2022 Dec; 8(48):eabo0876. PubMed ID: 36459552
[TBL] [Abstract][Full Text] [Related]
3. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy.
Khalil BD; Sanchez R; Rahman T; Rodriguez-Tirado C; Moritsch S; Martinez AR; Miles B; Farias E; Mezei M; Nobre AR; Singh D; Kale N; Sproll KC; Sosa MS; Aguirre-Ghiso JA
J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34812843
[TBL] [Abstract][Full Text] [Related]
4. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression.
Li H; Li Q; Dang K; Ma S; Cotton JL; Yang S; Zhu LJ; Deng AC; Ip YT; Johnson RL; Wu X; Punzo C; Mao J
Cell Rep; 2019 Dec; 29(10):3200-3211.e4. PubMed ID: 31801083
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of imidazo[1,2-a]pyrazine derivatives as small molecule Gαq/11 inhibitors against uveal melanoma.
Deng JJ; Liu L; Ge Y; Song Z; Huang J; Fan G; Xiong XF
Eur J Med Chem; 2022 Sep; 239():114520. PubMed ID: 35716516
[TBL] [Abstract][Full Text] [Related]
6. Regulator of G protein signaling 2 inhibits Gα
Zhang Q; Haak AJ; Sjögren B
J Biol Chem; 2022 Jun; 298(6):101955. PubMed ID: 35452684
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of quinazoline derivatives as Gαq/11 proteins inhibitors against uveal melanoma.
Fan G; Liu L; Ye J; Xiao W; Xiong XF
Bioorg Chem; 2024 Feb; 143():107005. PubMed ID: 38043397
[TBL] [Abstract][Full Text] [Related]
8. NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.
Sosa MS; Parikh F; Maia AG; Estrada Y; Bosch A; Bragado P; Ekpin E; George A; Zheng Y; Lam HM; Morrissey C; Chung CY; Farias EF; Bernstein E; Aguirre-Ghiso JA
Nat Commun; 2015 Jan; 6():6170. PubMed ID: 25636082
[TBL] [Abstract][Full Text] [Related]
9. IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.
Lapadula D; Lam B; Terai M; Sugase T; Tanaka R; Farias E; Kadamb R; Lopez-Anton M; Heine CC; Modasia B; Aguirre-Ghiso JA; Aplin AE; Sato T; Benovic JL
Mol Cancer Ther; 2023 Jan; 22(1):63-74. PubMed ID: 36223548
[TBL] [Abstract][Full Text] [Related]
10. Discovery of small molecule G
Ge Y; Deng JJ; Zhu J; Liu L; Ouyang S; Song Z; Zhang X; Xiong XF
Acta Pharm Sin B; 2022 Aug; 12(8):3326-3340. PubMed ID: 35967274
[TBL] [Abstract][Full Text] [Related]
11. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
[TBL] [Abstract][Full Text] [Related]
12. Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry.
Arang N; Lubrano S; Rigiracciolo DC; Nachmanson D; Lippman SM; Mali P; Harismendy O; Gutkind JS
J Biol Chem; 2023 Feb; 299(2):102866. PubMed ID: 36596361
[TBL] [Abstract][Full Text] [Related]
13. Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish.
Mouti MA; Dee C; Coupland SE; Hurlstone AF
Oncotarget; 2016 Jun; 7(26):39654-39670. PubMed ID: 27166257
[TBL] [Abstract][Full Text] [Related]
14. NR2F1 contributes to cancer cell dormancy, invasion and metastasis of salivary adenoid cystic carcinoma by activating CXCL12/CXCR4 pathway.
Gao XL; Zheng M; Wang HF; Dai LL; Yu XH; Yang X; Pang X; Li L; Zhang M; Wang SS; Wu JB; Tang YJ; Liang XH; Tang YL
BMC Cancer; 2019 Jul; 19(1):743. PubMed ID: 31357956
[TBL] [Abstract][Full Text] [Related]
15. Atypical activation of the G protein Gα
Maziarz M; Leyme A; Marivin A; Luebbers A; Patel PP; Chen Z; Sprang SR; Garcia-Marcos M
J Biol Chem; 2018 Dec; 293(51):19586-19599. PubMed ID: 30352874
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide CRISPR knockout screening identified G protein pathway suppressor 2 as a novel tumor suppressor for uveal melanoma metastasis.
Shi S; Chen H; Wang H; Wan J; Shi Y; Li J; Wang S; Shi J; Lv J; Wu T; Wang L; Sun F
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3349-3360. PubMed ID: 35941228
[TBL] [Abstract][Full Text] [Related]
18. Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
[TBL] [Abstract][Full Text] [Related]
19. MITF deficiency accelerates GNAQ-driven uveal melanoma.
Phelps GB; Hagen HR; Amsterdam A; Lees JA
Proc Natl Acad Sci U S A; 2022 May; 119(19):e2107006119. PubMed ID: 35512098
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Evaluation of Small Molecule Gαq/11 Protein Inhibitors for the Treatment of Uveal Melanoma.
Ge Y; Shi S; Deng JJ; Chen XP; Song Z; Liu L; Lou L; Zhang X; Xiong XF
J Med Chem; 2021 Mar; 64(6):3131-3152. PubMed ID: 33715360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
